Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep:183:106374.
doi: 10.1016/j.phrs.2022.106374. Epub 2022 Jul 28.

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

Elisa Lazzaroni  1 , Maria Elena Lunati  2 , Laura Montefusco  2 , Ida Pastore  2 , Enrica Chebat  2 , Vincenzo Cimino  3 , Paola Silvia Morpurgo  2 , Milena Muratori  2 , Laura Plebani  2 , Andrea Bolla  2 , Antonio Rossi  2 , Luciana Vallone  2 , Alessandra Gandolfi  2 , Camilla Tinari  2 , Francesca D'Addio  1 , Moufida Ben Nasr  4 , Cristian Loretelli  4 , Cristiana Scaranna  5 , Rosalia Bellante  5 , Roberto Manfrini  6 , Fabrizio Muratori  7 , Ivano Franzetti  8 , Emanuela Orsi  9 , Carmine Gazzaruso  10 , Renata Ghelardi  11 , Paolo Desenzani  12 , Stefano Genovese  13 , Angela Girelli  14 , Franco Folli  6 , Cesare Berra  15 , Paolo Fiorina  16
Affiliations

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

Elisa Lazzaroni et al. Pharmacol Res. 2022 Sep.

Abstract

Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (-0.6 ± 1.8%) as well as in BMI (-1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D.

Keywords: Albuminuria; Cardio-vascular risk; Dapagliflozin; Hb1Ac.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types